Fig. 5: A high CD8B/FOXP3 gene expression ratio is associated with increased survival in patients treated with NACT + P. | Nature Communications

Fig. 5: A high CD8B/FOXP3 gene expression ratio is associated with increased survival in patients treated with NACT + P.

From: Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

Fig. 5

A, C PFS (left) and OS (right) curves according to the CD8B/FOXP3 expression ratio (High NACT (red), n = 14; Low NACT (dark blue), n = 7; High NACT + P (orange), n = 17; Low NACT + P (light blue), n = 15) (A) and the CD8B/ENTPD1 expression ratio (High NACT (red), n = 13; Low NACT (dark blue), n = 8; High NACT + P (orange), n = 20; Low NACT + P (light blue), n = 12) (C) in each arm. Patients were stratified based on the best cutoff. Statistical comparison of survival curves for NACT + P High vs. NACT High was performed using the likelihood ratio test. B Spearman correlation between log2(TPM + 1) FOXP3 and ENTPD1 gene expression. Error bands represents the 95% CI as a shaded gray area. Source data are provided as a Source Data file.

Back to article page